Higher-dose semaglutide injection specifically approved for chronic weight management and obesity treatment.
Adults with obesity (BMI ≥30) seeking weight loss
GLP-1 receptor agonist for diabetes and weight management with established clinical data.
Type 2 diabetes management
Both contain semaglutide (same active ingredient) and are made by Novo Nordisk. Ozempic (0.5-2mg) is FDA-approved for type 2 diabetes. Wegovy (2.4mg, higher dose) is FDA-approved for chronic weight management. Wegovy produces greater average weight loss (~15-17%).
Ozempic is the diabetes treatment; Wegovy is the weight loss version. If you have diabetes, Ozempic is prescribed; if the goal is weight loss without diabetes, Wegovy is the indicated drug.
Choose Wegovy if
Adults with obesity (BMI ≥30) seeking weight loss
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
| Metric | Wegovy | Ozempic | Diff |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$1,300 | ~$900 | +44% |
| Maximum Weekly Dose(mg) | 7.2 mg (HD formulation) | 2.0 mg | +260% |
| FDA Approval Year(year) | 2021 | 2017 |
Wegovy vs Ozempic
products
Ozempic vs Wegovy
health
Ozempic vs Mounjaro
health
Tylenol vs Advil
health
Vegan vs Vegetarian
health
Almond Milk vs Oat Milk
health
Keto vs Paleo
health
Running vs Walking
health
Yoga vs Pilates
health
CrossFit vs Gym Training
health
Flu Shot vs COVID Vaccine
health
Organic Food vs Non-Organic Food
health
Choose Ozempic if
Type 2 diabetes management
| — |
| Number of Dose Strengths Available(strengths) | 5 | 4 | +25% |
| Typical Weight Loss at Maximum Dose(% of body weight) | 15-22% | 5-7% | +208% |
| FDA Approval Year(year) | 2021 (weight management) | 2017 (diabetes) | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% | — |
| Injection Frequency(times per week) | 1 | 1 | — |
| Average Monthly Cost (Uninsured)(USD) | $1,350-1,600 | $900-1,200 | +40% |
| Time to Maintenance Dose(weeks) | 16 | 12 | +33% |
| HbA1c Reduction in Diabetics(percentage points) | 0.5-1.0 | 1.5-2.0 | -57% |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | 1.5-2.0% | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | 2021 | — |
| Injection Schedule(per week) | Once weekly | Once weekly | — |
| Average Retail Price(USD/month) | $900-1,300 | $900-1,300 | — |
| Number of Dose Strengths Available(options) | 3 | 3 | — |
| Time on Market(years) | 9 years | 9 years | — |
All figures sourced from publicly available data. Last updated May 2026.
Wegovy
Obesity/weight loss
Ozempic
Type 2 diabetes
Wegovy
2.4mg🏆
Ozempic
0.5-2mg
Wegovy
15-17%🏆
Ozempic
~10%
Wegovy
~$1,300
Ozempic
~$900🏆
They contain the same active ingredient (semaglutide) but at different doses. Wegovy (2.4mg) is a higher dose approved for obesity; Ozempic (up to 2mg) is approved for type 2 diabetes.
Dive deeper with these curated resources
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more
| Attribute | ||
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Average Weight Loss(% body weight) | 15-22% | 8-12% |
| Typical Weight Loss at Maximum Dose(% of body weight) | 15-22% | 5-7% |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — |
| Monthly Cost (without insurance)(USD) | ~$1,300 | ~$900 |
| Average Monthly Cost (Uninsured)(USD) | $1,350-1,600 | $900-1,200 |
| Average Retail Price(USD/month) | $900-1,300 | — |
| Maximum Weekly Dose(mg) | 7.2 mg (HD formulation) | 2.0 mg |
| FDA Approval Year(year) | 2021 | 2017 |
| FDA Approval Year(year) | 2021 (weight management) | 2017 (diabetes) |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — |
| Primary Indication | Weight Loss & Obesity | Type 2 Diabetes |
| Cardiovascular Benefits | Proven in overweight/obese patients | Proven in diabetic patients |
| Typical Insurance Coverage | Limited coverage for weight loss | Widely covered for diabetes |
| Number of Dose Strengths Available(strengths) | 5 | 4 |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | Semaglutide (GLP-1 receptor agonist) |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% |
| Injection Frequency(times per week) | 1 | 1 |
| Injection Schedule(per week) | Once weekly | — |
| Time to Maintenance Dose(weeks) | 16 | 12 |
| HbA1c Reduction in Diabetics(percentage points) | 0.5-1.0 | 1.5-2.0 |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | — |
| Number of Dose Strengths Available(options) | 3 | — |
| Time on Market(years) | 9 years | — |
Side-by-side comparison of numeric attributes